Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The registry of COVID-19 patients was designed to collect epidemiolgical, demographic, clinical, anamnestic and outcome information together with serological and microbiological samples from COVID-19 patients admitted at the University Hospital of Verona (Azienda Ospedaliera Universitaria Integrata, AOUI Verona). All SARS-CoV 2 positive patients admitted and able to give an informed consent are included, irrespectively of age and gender.
Description: Epidemiological data including demographic data, contact with COVD-19 positive patients and onset of symptoms.
Measure: Epidemiological predictors of poor outcomes in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Underlying chronic diseases, signs/symptoms related with COVID-19 diseases an clinical presentation on admission
Measure: Clinical predictors of poor outcomes in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Body temperature (°C)
Measure: Body temperature (°C) on admission in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Blood pressure (mmHg)
Measure: Blood pressure (mmHg) on admission in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Pulse rate (beats per minute)
Measure: Pulse rate (beats per minute) on admission in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Pulse rate (beats per minute)
Measure: Respiratory rate (breaths per minute) on admission in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Peripheral oxygen saturation (%)
Measure: Peripheral oxygen saturation (%) on admission in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: CRP (m/gL)
Measure: C reactive protein (CRP, m/gL) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: PCT (ng/mL
Measure: Procalcitonin (PCT, ng/mL) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: White Blood Count (WBC, cell/mm3)
Measure: White Blood Count (WBC, cell/mm3) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Neutrophils (cell/mm3)
Measure: Neutrophils (cell/mm3) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Lymphocytes (cell/mm3)
Measure: Lymphocytes (cell/mm3) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Platelets (cell/mm3)
Measure: Platelets (cell/mm3) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: LDH (mU/ml)
Measure: L-lattato deidrogenasi (LDH, mU/ml) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: CK (U/L)
Measure: Creatine kinase (CK, U/L) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: D-dimer (μg/L)
Measure: D-dimer (μg/L) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: fibrinogen (g/L)
Measure: fibrinogen (g/L) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: ferritin (mcg/L)
Measure: ferritin (mcg/L) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: AST (U/L)
Measure: AST (U/L) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: ALT (U/L)
Measure: ALT (U/L) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: Creatinine (mg/dl)
Measure: Creatinine (mg/dl) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: pH
Measure: Arterial blood gas anaysis pH in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: pO2 (mmHg)
Measure: Arterial blood gas anaysis pO2 (mmHg) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: pCO2 (mmHg)
Measure: Arterial blood gas anaysis pCO2 (mmHg) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: HCO3 (mmol/l)
Measure: Arterial blood gas anaysis HCO3 (mmol/l) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: SpO2 (%)
Measure: Arterial blood gas anaysis SpO2 (%) in COVID-19 patients admitted to University Hospital of Verona Time: through study completion, an average of 3 monthsDescription: IL-6 (pg/mL)
Measure: Host-related factors associated with the pathogenesis of COVID-19 Time: through study completion, an average of 3 monthsDescription: Nasal and rectal swabs, fecal samples and blood samples
Measure: Virological factors associated with the pathogenesis of COVID-19 Time: through study completion, an average of 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports